Browse Studies — Arctuva

Phase 2

A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

DALY II USA is a phase II, multi-center, single arm study to evaluate the efficacy, safety, and pharmacokinetics of zamtocabtagene autoleucel (MB-CART2019.1) i…

Refractory Diffuse Large B Cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell LymphomaHigh Grade B-cell Lymphoma (HGBCL)+6 more

Estimated

~$10 – $8,750

Miltenyi Biomedicine GmbHNCT04792489

Phase 1

A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting t…

Refractory Non-Hodgkin LymphomaBurkitt LymphomaMantle Cell Lymphoma+7 more

Estimated

~$10 – $7,500

C. Babis AndreadisNCT04545762

Phase 1

Acalabrutinib Maintenance Following Cellular Therapy for Large B-Cell Lymphoma Patients at Very High Risk for Relapse

This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lym…

Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaTransformed Lymphoma+1 more

Estimated

~$10 – $6,250

Jonsson Comprehensive Cancer CenterNCT05256641

Phase 2

A Feasibility Study Following a Phase 2a Design to Demonstrate Successful Local Manufacture of Chimeric Antigen Receptor (CAR) T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

This trial aims to demonstrate the feasibility of this approach to reliably generate product and to safely administer the product to patients who have B-Cell L…

B-Cell LymphomaB Acute Lymphoblastic LeukemiaDiffuse Large B Cell Lymphoma+6 more

Estimated

~$10 – $7,500

John ListerNCT05281809